A new subcutaneous formulation of amivantamab shows high efficacy and improved safety for advanced NSCLC patients, enhancing treatment convenience.
Sun Min Lim, MD, PhD
Advertisement
Sun Min Lim, MD, PhD, is a professor at Yonsei University Cancer Center in Seoul, Republic of Korea.
Articles by Sun Min Lim, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5